CN-122005542-A - Application of schisandrin B in preparation of medicine for preventing and/or treating diabetic nephropathy

Abstract

The invention provides application of schisandrin B in preparation of a medicament for preventing and/or treating diabetic nephropathy, and belongs to the technical field of biological medicines. The invention applies the metabolite to the screening of drugs for preventing and treating diabetic nephropathy, researches show that pyrimidine metabolic disturbance exists in the bodies of diabetic nephropathy patients, schisandrin B and pyrimidine metabolic key enzyme have better binding capacity, and the activity level of HK-2 cells in the diabetic nephropathy disease state with high sugar simulation can be effectively improved. The study of the present invention found that 5. Mu.M schisandrin B treated HK-2 cells showed a significant increase in cell morphology, activity and number after 48 hours compared to HK-2 cells in a high-sugar mimetic diabetic nephropathy disease state without any drug treatment.

Inventors

• ZHONG MEIRONG
• LIU XUEMEI
• LIU XIU
• WANG ZENGYOU
• LI YUBO
• GONG XUE
• WANG YUMING
• SUN GUIJIANG
• LI BO
• DAI WENBO
• ZHENG SHAOXIONG
• LIU XIAODONG

Assignees

• 天津医科大学第二医院

Dates

Publication Date

20260512

Application Date

20260309

Claims (10)

1. 1. Application of schisandrin B in preparing medicine for preventing and/or treating diabetic nephropathy.
2. 2. The use according to claim 1, wherein the schizandrin b is used for modulating DKD mouse pyrimidine metabolism.
3. 3. The use according to claim 1, wherein schizandrin is used for reducing peroxidative damage of kidney tissue.
4. 4. The use according to claim 3, wherein said schizandrin b inhibits kidney peroxidation damage by reducing kidney tissue MDA content, increasing SOD and GSH-Px activity.
5. 5. The use according to claim 1, wherein schizandrin b is used for improving kidney function index.
6. 6. The use according to claim 5, wherein the kidney function index comprises UACR, uric acid, urea nitrogen, creatinine, kidney index.
7. 7. The use according to claim 1, wherein the schizandrin b is used for improving kidney tissue pathology in DKD mice.
8. 8. The use according to claim 1, wherein said schizandrin is used for regulating specific metabolic changes in kidney tissue, said specific metabolism comprising lipid metabolism, glucose metabolism, TCA cycle, nucleotide metabolism and lipid metabolism.
9. 9. Application of schisandrin B in preparing medicine for treating renal cell injury is provided.
10. 10. The use according to claim 7, wherein the kidney cells are human kidney cortical proximal tubular epithelial cells.

Description

Application of schisandrin B in preparation of medicine for preventing and/or treating diabetic nephropathy Technical Field The invention relates to the technical field of biological medicines, in particular to application of schisandrin B in preparation of a medicine for preventing and/or treating diabetic nephropathy. Background Diabetes (DM) has become a major public health problem worldwide, with 96.0% being type II diabetes (T2 DM). In China, the overall prevalence of T2DM has reached 14.92%, diabetic nephropathy (DKD) is a common complication of DM, and the incidence of DKD in the T2DM population is about 20%40%. Notably, DKD is pathophysiologically complex and is affected by multiple factors, such as metabolism (blood glucose, blood pressure, blood lipid, etc.) and hemodynamics, thereby activating intracellular signaling pathways, inducing oxidative stress/insulin resistance/inflammation/epigenetic changes, etc., ultimately leading to kidney fibrosis/renal failure. The metabolites detected by metabolomics are considered to be closest to individual characterization, revealing a complex metabolic network of the disease and providing unique metabolic characteristics concerning the development and progression of the disease. Kidneys act as a highly metabolic organ and are susceptible to systemic metabolic disorders. Recent years have seen continuous research results that endogenous metabolites as end products can also serve as functional metabolites affecting all aspects of the histology landscape, from genome, epigenomic and transcriptomic to proteomic, mediating the physiological and pathological changes of the organism. Thus, the screening of DKD therapeutic drugs is facilitated from the metabolic level. Modern medical treatment DKD mainly adopts symptomatic treatment, namely hypoglycemic, hypolipidemic, antihypertensive and anti-inflammatory therapies. Whereas traditional Chinese medicine provides a unique view for DKD treatment, traditional Chinese medicine or active ingredients thereof produce remarkable treatment effects from different angles in a single or combined mode according to the etiology characteristics thereof. Therefore, the method for digging the DKD therapeutic drug from the traditional Chinese medicine has good application prospect. Approved clinical medicines and classical famous/clinical laboratory prescriptions provide a basis for the discovery of innovative traditional Chinese medicines. Wherein, the 'multi-component drug effect' of the traditional Chinese medicine is determined by the complex chemical substance basis, and the drug effect components are the core of the drug effect and the key of treating diseases. Therefore, the medicine research and development is carried out by using the 'old medicine', and the active ingredient research of the system can be carried out according to the high-efficiency chemical ingredient analysis, so that the active compound with clinical use value is found. Disclosure of Invention In view of the above, the invention aims to provide the application of schisandrin B in preparing the medicine for preventing and/or treating the diabetic nephropathy, and the application of the metabolite in the screening of the medicine for preventing and treating the diabetic nephropathy is researched, and the invention discovers that pyrimidine metabolic disturbance exists in a diabetic nephropathy patient, the schisandra chinensis and pyrimidine metabolic key enzyme have better binding capability, and the activity level of HK-2 cells in a diabetic nephropathy disease state simulated by high sugar can be effectively improved. In order to achieve the above object, the present invention provides the following technical solutions: In a first aspect, the invention provides application of schisandrin B in preparing a medicament for preventing and/or treating diabetic nephropathy. Preferably, the schisandrin b is used for regulating DKD mouse pyrimidine metabolism. Further preferably, schisandrin b regulates the body weight, food intake, water consumption, fasting glucose and oral glucose tolerance of DKD mice. Preferably, the schisandrin b is used for reducing peroxidative damage of kidney tissue. Preferably, the schisandrin B can reduce the MDA content of kidney tissues, improve the activity of SOD and GSH-Px and inhibit kidney peroxidation damage. Preferably, the schisandrin B is used for improving kidney function indexes. Preferably, the kidney function index includes UACR, uric acid, urea nitrogen, creatinine, and kidney index. Preferably, the schisandrin B is used for improving pathological changes of kidney tissues. Preferably, the schisandrin B is used for regulating specific metabolic changes in kidney tissues, wherein the specific metabolism comprises lipid metabolism, glucose metabolism, TCA (ternary content addressable memory) circulation, nucleotide metabolism and lipid metabolism. Further preferably, the schisandrin B can reduce serum TG, TC, LDL-c conte